Bartlett Family Professor of Gastrointestinal Oncology
Chief, Solid Tumor Services
Director, Gastrointestinal Oncology Program
Co-Director, Center for Advanced Digestive Care
Weill Cornell Medical College
New York, New York
Manish A. Shaw, MD, has disclosed that he has received funds for research support from Boston Biomedical and Roche.
Rachael M. Andrie, PhD, has no real or apparent conflicts of interest to report.
Megan K. Murphy, PhD, has no real or apparent conflicts of interest to report.
Editorial Director, Hematology/Oncology
Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.
Senior Managing Editor
Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This program is intended for physicians and other healthcare providers who care for patients with gastrointestinal cancers.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 26, 2017, through January 25, 2018:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
From Clinical Care Options (CCO), on-demand video featuring global experts on using PARP inhibitors for pancreatic cancer with BRCA1/2 mutations
In this commentary from Clinical Care Options (CCO), experts discuss second-line treatment after atezolizumab plus bevacizumab for patients with advanced HCC
Gain key insights quickly with this short slideset from Clinical Care Options (CCO) on HER2 testing and targeted therapy in advanced GI cancers
In this slideset from Clinical Care Options (CCO), experts provide insights on HER2 testing and targeted therapy in advanced gastrointestinal cancers